LONDON--(BUSINESS WIRE)--ViiV Healthcare, a global company focused on HIV and mostly owned by GSK, with Pfizer and Shionogi as partners, has shared new findings from two studies that show no new cases of HIV infection with Apretude, the only long-acting injectable approved for prevention. Additionally, real-world data for Cabenuva, the only complete long-acting injectable treatment available, demonstrated its effectiveness over the past three years.
Pfizer's stock stayed the same even as the S&P 500 fell by 2.25%, showing its stability in a cautious market. For the year 2024, the company reported revenue of $63.6 billion, which is a 6.7% increase from last year, with non-COVID sales rising by 12%, surpassing the expected growth of 9% to 11%. Additionally, Pfizer's research and development made progress with 12 approvals, 7 major study launches, and 8 Phase 3 results, enhancing its treatments for cancer and obesity.
We have just put together a list of the 10 Most Undervalued US Stocks to Buy Based on Hedge Fund Recommendations. In this article, we will examine how Pfizer Inc. (NYSE:PFE) compares to other undervalued US stocks. On a day when major market averages are down, Paul Hickey, co-founder of Bespoke Investment Group, and […]
Investors might continue holding onto PFE stock to observe how its new sources of growth do.
Recently, Pfizer (PFE) has gained a lot of interest from users on Zacks.com. As a result, it's important to understand the factors that could affect the stock's future.
A significant drop in Wall Street's top stock index presents a chance for investors who focus on value. This decline could lead to potential investments for those looking for good deals. Value investors may find this situation advantageous.
Johnson & Johnson and Pfizer are both top companies in the healthcare industry. They each have their strengths and weaknesses when it comes to their range of medications. This article will explore which company is a better option for long-term investors.
On Thursday, Pfizer announced that James List will lead its Internal Medicine portfolio, which focuses on creating medicines for cardiovascular issues and obesity.
The Investment Committee discusses their final trading decisions.
PHILADELPHIA, March 05, 2025 (GLOBE NEWSWIRE) -- Berger Montague is informing Pfizer Inc. shareholders about an investigation into the company's Board of Directors. This investigation looks into possible violations of their responsibilities to Pfizer and its shareholders related to the marketing and sale of Depo-Provera.